{"id":"https://openalex.org/W7148669162","doi":"https://doi.org/10.1158/1538-7445.am2026-6441","title":"Abstract 6441: Safety profile of post-CDK4/6 treatments in HR+/HER2\u2212 metastatic breast cancer (mBC): A network meta-analysis","display_name":"Abstract 6441: Safety profile of post-CDK4/6 treatments in HR+/HER2\u2212 metastatic breast cancer (mBC): A network meta-analysis","publication_year":2026,"publication_date":"2026-04-03","ids":{"openalex":"https://openalex.org/W7148669162","doi":"https://doi.org/10.1158/1538-7445.am2026-6441"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2026-6441","doi":"https://doi.org/10.1158/1538-7445.am2026-6441","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-6441","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004302913","display_name":"Martina Pagliuca","orcid":"https://orcid.org/0000-0001-8114-2577","observed_orcids":["https://orcid.org/0000-0001-8114-2577"]},"institutions":[{"id":"https://openalex.org/I4210149489","display_name":"Scuola Superiore Meridionale","ror":"https://ror.org/04swxte59","country_code":"IT","type":"education","lineage":["https://openalex.org/I4210149489"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Martina Pagliuca","raw_affiliation_strings":["1Scuola Superiore Meridionale, Napoli, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Scuola Superiore Meridionale, Napoli, Italy;","institution_ids":["https://openalex.org/I4210149489"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009712410","display_name":"Roberto Buonaiuto","orcid":"https://orcid.org/0000-0002-5495-3224","observed_orcids":["https://orcid.org/0000-0002-5495-3224"]},"institutions":[{"id":"https://openalex.org/I4210149489","display_name":"Scuola Superiore Meridionale","ror":"https://ror.org/04swxte59","country_code":"IT","type":"education","lineage":["https://openalex.org/I4210149489"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Roberto Buonaiuto","raw_affiliation_strings":["1Scuola Superiore Meridionale, Napoli, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Scuola Superiore Meridionale, Napoli, Italy;","institution_ids":["https://openalex.org/I4210149489"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025684262","display_name":"Michelino De Laurentiis","orcid":"https://orcid.org/0000-0001-9009-1572","observed_orcids":["https://orcid.org/0000-0001-9009-1572"]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Michelino De Laurentiis","raw_affiliation_strings":["2Istituto Nazionale Tumori IRCCS \"Fondazione G.Pascale\", Napoli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Istituto Nazionale Tumori IRCCS \"Fondazione G.Pascale\", Napoli, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026237890","display_name":"Carmine De Angelis","orcid":"https://orcid.org/0000-0003-1158-4630","observed_orcids":["https://orcid.org/0000-0003-1158-4630"]},"institutions":[{"id":"https://openalex.org/I4210149489","display_name":"Scuola Superiore Meridionale","ror":"https://ror.org/04swxte59","country_code":"IT","type":"education","lineage":["https://openalex.org/I4210149489"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Carmine De Angelis","raw_affiliation_strings":["1Scuola Superiore Meridionale, Napoli, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Scuola Superiore Meridionale, Napoli, Italy;","institution_ids":["https://openalex.org/I4210149489"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"86","issue":"7_Supplement","first_page":"6441","last_page":"6441"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hr-her2-metastatic-breast-cancer","display_name":"HR+/HER2- metastatic breast cancer","score":0.9520000219345093},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.902999997138977},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.7260000109672546},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.8090000152587891},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9390000104904175},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.7789999842643738},{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.925000011920929},{"id":"https://openalex.org/keywords/datopotamab-deruxtecan","display_name":"datopotamab deruxtecan","score":0.9670000076293945},{"id":"https://openalex.org/keywords/imlunestrant","display_name":"imlunestrant","score":0.7160000205039978},{"id":"https://openalex.org/keywords/camizestrant","display_name":"camizestrant","score":0.9940000176429749},{"id":"https://openalex.org/keywords/elacestrant","display_name":"elacestrant","score":0.996999979019165},{"id":"https://openalex.org/keywords/protacs","display_name":"PROTACs","score":0.531000018119812},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8343999981880188},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.6883999705314636},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6478999853134155},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6410999894142151},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6031000018119812},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5730999708175659},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4887999892234802},{"id":"https://openalex.org/C162376815","wikidata":"https://www.wikidata.org/wiki/Q2158281","display_name":"Frequentist inference","level":4,"score":0.45210000872612},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.448199987411499},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.4410000145435333},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.4332999885082245},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.427700012922287},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35089999437332153},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3418999910354614},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.28220000863075256},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2800999879837036},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.26820001006126404},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.26089999079704285},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2578999996185303}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2026-6441","doi":"https://doi.org/10.1158/1538-7445.am2026-6441","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-6441","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8951466083526611,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Several":[1],"treatments":[2,314],"(tx)":[3],"are":[4,243],"available":[5],"for":[6,34,52,110,182,191,197,216,227,233,288,331],"HR+/HER2-":[7],"mBC;":[8],"however,":[9],"choosing":[10],"subsequent":[11],"tx":[12,36,50,82,86,157,296],"after":[13],"progression":[14],"on":[15,160],"first-line":[16],"CDK4/6":[17],"inhibitor":[18],"+":[19],"endocrine":[20],"therapy":[21],"(ET)":[22],"remains":[23],"challenging.":[24],"Assessing":[25],"the":[26,46,102,170,207,257,328],"safety":[27,47,111],"profiles":[28],"of":[29,48,63,260,282,312,327],"these":[30],"options":[31],"is":[32],"crucial":[33],"guiding":[35],"selection.":[37],"We":[38],"performed":[39,100],"a":[40,60,137,277],"network":[41,322],"meta-analysis":[42,323],"(NMA)":[43],"to":[44,72,124,200,236],"compare":[45],"systemic":[49],"approved":[51],"this":[53],"setting.":[54],"Tx":[55],"strategies":[56],"were":[57,83,126,146,173,210],"retrieved":[58],"through":[59],"systematic":[61],"review":[62],"randomized":[64],"phase":[65],"II-III":[66],"trials":[67],"published":[68],"from":[69,128],"January":[70],"2014":[71],"October":[73],"2025":[74],"(PROSPERO":[75],"CRD420251234039)":[76],"and":[77,121,134,156,241,254,262],"only":[78],"FDA-":[79],"and/or":[80],"EMA-approved":[81],"included.":[84],"Each":[85],"was":[87,99],"compared":[88],"with":[89,151,274],"standard":[90],"ET":[91],"or":[92],"chemotherapy":[93],"(CT).":[94],"A":[95,321],"frequentist":[96],"random-effects":[97,138],"NMA":[98,163],"using":[101,131,136],"netmeta":[103],"package":[104],"in":[105,245,315],"R.":[106],"Risk":[107],"ratios":[108],"(RRs)":[109],"outcomes":[112],"(grade[G]":[113],"\u22653":[114],"adverse":[115],"events":[116],"[AEs],":[117],"any":[118,183,217,283],"grade":[119],"AEs,":[120],"AEs":[122,198,219,234,285,292],"leading":[123,199,235],"discontinuation)":[125],"calculated":[127],"each":[129],"trial":[130],"pairwise":[132],"comparisons":[133],"pooled":[135],"model":[139],"estimated":[140,239],"by":[141],"restricted":[142],"maximum":[143],"likelihood.":[144],"Results":[145],"shown":[147,244],"as":[148,276],"forest":[149],"plots":[150],"95%":[152,179],"confidence":[153],"intervals":[154],"(CI),":[155],"ranked":[158],"based":[159],"P-scores.":[161],"The":[162,238],"included":[164],"16":[165],"trials.":[166],"Among":[167,247,265],"ET-based":[168,248],"strategies,":[169],"lowest":[171,208,258],"RRs":[172,209,240],"observed":[174,211],"for:":[175,212],"imlunestrant":[176],"alone":[177],"(0.98,":[178],"CI":[180],"0.92-1.05)":[181],"G":[184,218,284],"AEs;":[185,193,229],"camizestrant":[186],"75":[187],"mg":[188],"(0.81,":[189],"0.36-1.83)":[190],"G\u22653":[192,228,263,291],"elacestrant":[194],"(1.45,":[195],"0.66-3.16)":[196],"discontinuation.":[201,237],"While":[202],"among":[203],"antibody-drug":[204],"conjugates":[205],"(ADCs)":[206],"sacituzumab":[213],"govitecan":[214],"(SG)":[215],"(1.00,":[220],"0.99-1.01);":[221],"datopotamab":[222],"deruxtecan":[223],"(Dato-DXd)":[224],"(0.47,":[225],"0.37-0.59)":[226],"SG":[230],"(0.83,":[231],"0.26-2.66)":[232],"P-scores":[242],"table.":[246],"options,":[249],"novel":[250],"mono-ETs":[251],"(oral":[252],"SERDs":[253],"PROTACs)":[255],"showed":[256,279],"risk":[259,293],"discontinuation":[261],"AEs.":[264],"ADCs,":[266],"TROP2-directed":[267],"agents":[268],"had":[269],"fewer":[270],"discontinuations,":[271],"while":[272],"ADCs":[273],"DXd":[275],"payload":[278],"higher":[280],"rates":[281],"but":[286],"(except":[287],"DESTINY-Breast06)":[289],"lower":[290],"than":[294],"other":[295],"strategies.":[297],"Citation":[298],"Format:":[299],"Martina":[300],"Pagliuca,":[301],"Roberto":[302],"Buonaiuto,":[303],"Michelino":[304],"De":[305,308],"Laurentiis,":[306],"Carmine":[307],"Angelis.":[309],"Safety":[310],"profile":[311],"post-CDK4/6":[313],"HR+/HER2\u2212":[316],"metastatic":[317],"breast":[318],"cancer":[319],"(mBC):":[320],"[abstract].":[324],"In:":[325],"Proceedings":[326],"American":[329],"Association":[330],"Cancer":[332,350],"Research":[333],"Annual":[334],"Meeting":[335],"2026;":[336],"Part":[337],"1":[338],"(Regular":[339],"Abstracts);":[340],"2026":[341],"Apr":[342],"17-22;":[343],"San":[344],"Diego,":[345],"CA.":[346],"Philadelphia":[347],"(PA):":[348],"AACR;":[349],"Res":[351],"2026;86(7":[352],"Suppl):Abstract":[353],"nr":[354],"6441.":[355]},"counts_by_year":[],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2026-04-04T00:00:00"}